Sionna Therapeutics Cuts 46% of Staff After Cystic Fibrosis Add-On Drug Fails Trial
- Sionna Therapeutics is cutting approximately 46% of its workforce as part of a broader strategic restructuring.
- The move follows the failure of a clinical trial testing SION-719, an NBD1 stabilizer, as an add-on cystic fibrosis (CF) therapy.
- SION-719 was tested alongside Vertex Pharmaceuticals' Trikafta in CF patients homozygous for the F508del mutation.
- The trial did not produce a statistically significant reduction in sweat chloride, a standard biomarker used to gauge CFTR modulator efficacy in CF.
- Sionna's program had aimed to build on and improve outcomes beyond the market-leading Trikafta regimen.
- The layoffs and pipeline reprioritization mark a strategic shift for the company following this clinical setback.
Trikafta's add-on moat just claimed another name. SION-719 joins a growing list of CF programs that have failed to clear the sweat-chloride bar once layered on top of triple-combo therapy — a pattern that says less about any one company's execution and more about how close to a ceiling Trikafta already sits. That's the more interesting read for the mechanism itself: NBD1 stabilization is scientifically rational (Vertex runs its own NBD1 programs internally), yet delivering a clean, statistically significant delta on top of an already-near-maximal correction is proving brutally hard across the class, not just for Sionna. A 46% headcount cut is not routine trimming — it's a company betting its remaining cash runway on a sharply narrowed, likely earlier-stage pipeline rather than continuing broad-front development. Net effect for the competitive landscape: one fewer credible Trikafta challenger, which further entrenches Vertex's CF monopoly and eases pressure on both its pricing power and its own pipeline urgency.
Sionna lays off 46% of workforce in strategic shift after cystic fibrosis trial fail ↗